Delcath SystemsDCTH -0.41%70 FCF Margin % is 1.15% as of Mar. 2026. GuruFocus rates DCTH with a GF Score™ of 70/100 and a GF Value™ of $36.67 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Delcath Systems ranks better than 91.41% on this metric.
The historical rank and industry rank for Delcath Systems's FCF Margin % or its related term are showing as below:
DCTH'
s FCF Margin % Range Over the Past 10 Years
Min: -1516.17 Med: -683.16 Max: 24.6
Current: 21.22
During the past 13 years, the highest FCF Margin % of Delcath Systems was 24.60%. The lowest was -1516.17%. And the median was -683.16%.
DCTH's FCF Margin % is ranked better than 91.41% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs DCTH: 21.22
Delcath Systems FCF Margin % Related Terms
Delcath Systems FCF Margin % Historical Data
* Premium members only.
The historical data trend for Delcath Systems's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Delcath Systems's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Delcath Systems FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Delcath Systems's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Delcath Systems's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Delcath Systems (DCTH) has a FCF Margin % of 1.15% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Delcath Systems and its competitors. According to the industry distribution chart, Delcath Systems ranks #70 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 8.6%.
Is Delcath Systems' FCF Margin % too high?
Delcath Systems' current FCF Margin % is 1.15%. Based on the distribution chart, Delcath Systems ranks #70 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Delcath Systems has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' FCF Margin % compare to OFIX and VMD?
According to the Medical Devices & Instruments industry distribution chart, Delcath Systems ranks #70 out of 815 companies for FCF Margin %. This places Delcath Systems in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Delcath Systems and its competitors. Delcath Systems's current FCF Margin % is 1.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $36.67, compared to a current price of $12.23 — trading 66.6% below its estimated fair value. The current FCF Margin % is 1.15%. Delcath Systems' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Delcath Systems (DCTH), the current FCF Margin % is 1.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Delcath Systems (DCTH) Overvalued in 2026?
Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued.
The current stock price of $12.23 is trading 66.6% below its estimated GF Value™ of $36.67.
GuruFocus considers Delcath Systems to be Significantly Undervalued.
Key valuation signals for DCTH:
FCF Margin %: 1.15%
GF Value™: $36.67 vs. price of $12.23 (66.6% below fair value)
No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
70GF Score
Get the complete analysis for DCTH
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCTH has been successfully added to your 
